Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Banco de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Gynecol Endocrinol ; 34(10): 900-904, 2018 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-29671363

RESUMEN

Tubulin beta eight class VIII (TUBB8) is a subtype of ß-tubulin that only exists in primates. Mutations in the TUBB8 gene have been proven to cause oocyte maturation arrest. The aim of this study was to identify the new types of mutations in TUBB8. Six women (families) with oocyte maturation arrest and 100 healthy controls were recruited. The sequence of the TUBB8 gene was amplified and analyzed by Sanger sequencing, which revealed a de novo heterozygous variant c.292G > A (p.G98R) of TUBB8 in one affected individual. This TUBB8 variant was absent in the 100 fertile females and was predicted to be highly damaging to the function of the TUBB8 protein by SIFT and PolyPhen-2. This novel variant extends the spectrum of TUBB8 mutations and the presence of a TUBB8 mutation is being considered to be indicative of a poor prognosis for the success of assisted reproductive treatment.


Asunto(s)
Infertilidad Femenina/genética , Mutación , Oocitos/metabolismo , Oogénesis/genética , Tubulina (Proteína)/genética , Adulto , Análisis Mutacional de ADN , Femenino , Humanos
2.
Taiwan J Obstet Gynecol ; 55(3): 399-404, 2016 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-27343323

RESUMEN

OBJECTIVE: No treatment is recommended for routine maintenance tocolysis after an arrested preterm birth. Our present study aimed to evaluate the effect of progesterone and nifedipine as maintenance tocolysis therapy after an arrested preterm birth. MATERIALS AND METHODS: For relevant studies, we systematically searched the literature in databases of PubMed, Embase, and the Cochrane Central Register of Controlled Trials (CENTRAL) in the Cochrane Library. Only randomized controlled trials were included. RESULTS: Nine trials were included in our review. Nifedipine and progesterone were used for maintenance tocolysis. Compared to placebo treatment or no treatment, maintenance tocolysis with progesterone could significantly prolong the delivery gestational weeks [standard mean difference (SMD) 1.64; 95% confidence interval (CI), 1.21, 2.07; p < 0.00001], reduce the proportion of patients with delivery before 37 weeks (risk ratio 0.63; 95% CI, 0.47, 0.83; p = 0.001), and increase the birth weight (SMD 317.71; 95% CI, 174.89, 460.53; p < 0.0001). However, no such benefits were observed after maintenance tocolysis with nifedipine. Both nifedipine and progesterone had no significant influences on the following outcomes: neonatal intensive care unit stay, proportion of neonatal intensive care unit admission, neonatal mortality, and incidence of respiratory distress syndrome. CONCLUSION: Our results with maintenance tocolysis with progesterone may be useful for patients who had an episode of threatened preterm labor successfully treated with acute tocolytic therapy.


Asunto(s)
Nifedipino/uso terapéutico , Trabajo de Parto Prematuro/tratamiento farmacológico , Progesterona/uso terapéutico , Progestinas/uso terapéutico , Tocólisis/métodos , Tocolíticos/uso terapéutico , Quimioterapia Combinada , Femenino , Humanos , Quimioterapia de Mantención , Embarazo , Ensayos Clínicos Controlados Aleatorios como Asunto
3.
Eur J Drug Metab Pharmacokinet ; 41(4): 465-8, 2016 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-25737032

RESUMEN

Metabolism-mediated drug adverse effects (e.g., drug-drug interaction, bioactivation, etc.) strongly limit the utilization of clinical drugs. The present study aims to predict the metabolic capability of cytochrome P450 (CYP) 3A4 toward pazopanib which is an excellent drug exhibiting therapeutic role toward various cancers especially for ovarian cancer. Pazopanib can be well docked into the activity cavity of CYP3A4, and the interaction structure in pazopanib was methyl group located besides nitrogen in the five-membered ring. The distance between the hydrogen atom in methyl group and active center is 3.64 Å. The interaction amino acid is Glu374. Furthermore, both pazopanib and ketoconazole were docked into the activity cavity of CYP3A4 to compare their binding potential. The distance between ketoconazole and activity center (2.10 Å) is closer than the distance between pazopanib and activity center of CYP3A4, indicating the easy influence of CYP3A4 inhibitor toward the metabolism of pazopanib. All these data were helpful for the clinical application of pazopanib, and R&D of other tinib drug candidates as new anti-tumor drugs.


Asunto(s)
Antineoplásicos/metabolismo , Citocromo P-450 CYP3A/metabolismo , Pirimidinas/metabolismo , Sulfonamidas/metabolismo , Aminoácidos/metabolismo , Antineoplásicos/farmacología , Inhibidores Enzimáticos del Citocromo P-450/farmacología , Interacciones Farmacológicas/fisiología , Femenino , Humanos , Indazoles , Cetoconazol/farmacología , Simulación del Acoplamiento Molecular/métodos , Neoplasias Ováricas/tratamiento farmacológico , Oxidación-Reducción , Pirimidinas/farmacología , Sulfonamidas/farmacología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA